OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study
Yuming Sun, Liping Jin, Yating Dian, et al.
EClinicalMedicine (2023) Vol. 59, pp. 101981-101981
Open Access | Times Cited: 45
Yuming Sun, Liping Jin, Yating Dian, et al.
EClinicalMedicine (2023) Vol. 59, pp. 101981-101981
Open Access | Times Cited: 45
Showing 1-25 of 45 citing articles:
Effectiveness of azvudine in reducing mortality of COVID-19 patients: a systematic review and meta-analysis
Yaqi Wang, Huaiya Xie, Luo Wang, et al.
Virology Journal (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 9
Yaqi Wang, Huaiya Xie, Luo Wang, et al.
Virology Journal (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 9
Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study
Shuxia Wang, Jin Sun, Xin Zhang, et al.
EClinicalMedicine (2024) Vol. 69, pp. 102468-102468
Open Access | Times Cited: 8
Shuxia Wang, Jin Sun, Xin Zhang, et al.
EClinicalMedicine (2024) Vol. 69, pp. 102468-102468
Open Access | Times Cited: 8
Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study
Zhiguo Zhou, He Zheng, Gui’e Xiao, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Zhiguo Zhou, He Zheng, Gui’e Xiao, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study
Haiyu Wang, Guangying Cui, Ming Cheng, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Haiyu Wang, Guangying Cui, Ming Cheng, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy
Jiayuan Le, Yuming Sun, Guangtong Deng, et al.
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access
Jiayuan Le, Yuming Sun, Guangtong Deng, et al.
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access
Antiviral effectiveness and safety of azvudine in hospitalized SARS‐CoV‐2 patients with pre‐existing chronic respiratory diseases: A multicenter, retrospective cohort study
Junyi Sun, Mengzhao Yang, Daoke Yao, et al.
View (2025)
Open Access
Junyi Sun, Mengzhao Yang, Daoke Yao, et al.
View (2025)
Open Access
Effectiveness and Safety of Oral Azvudine for Elderly Hospitalized Patients With COVID‐19: A Multicenter, Retrospective, Real‐World Study
Ranran Sun, Haiyu Wang, Junyi Sun, et al.
Advanced Science (2025)
Open Access
Ranran Sun, Haiyu Wang, Junyi Sun, et al.
Advanced Science (2025)
Open Access
A multicenter, real-world cohort study: effectiveness and safety of Azvudine in hospitalized COVID-19 patients with pre-existing diabetes
Yongjian Zhou, Zecheng Yang, Shixi Zhang, et al.
Frontiers in Endocrinology (2025) Vol. 16
Open Access
Yongjian Zhou, Zecheng Yang, Shixi Zhang, et al.
Frontiers in Endocrinology (2025) Vol. 16
Open Access
The Antiviral Efficacy and Safety of Azvudine in Hospitalized SARS‐CoV‐2 Infected Patients with Liver Diseases Based on a Multicenter, Retrospective Cohort Study
Junyi Sun, Mengzhao Yang, Guanyue Su, et al.
Advanced Science (2025)
Open Access
Junyi Sun, Mengzhao Yang, Guanyue Su, et al.
Advanced Science (2025)
Open Access
Azvudine reduces the in-hospital mortality of COVID-19 patients: A retrospective cohort study
Kaican Zong, Hui Zhou, Wen Li, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 11, pp. 4655-4660
Open Access | Times Cited: 14
Kaican Zong, Hui Zhou, Wen Li, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 11, pp. 4655-4660
Open Access | Times Cited: 14
Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study
Qinqin Zhao, Bei Zheng, Bing Han, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 8, pp. 2087-2102
Open Access | Times Cited: 13
Qinqin Zhao, Bei Zheng, Bing Han, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 8, pp. 2087-2102
Open Access | Times Cited: 13
Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study
Xiang Zhao, Yuan Cheng, Meng Zhang, et al.
Infection and Drug Resistance (2023) Vol. Volume 16, pp. 6053-6060
Open Access | Times Cited: 12
Xiang Zhao, Yuan Cheng, Meng Zhang, et al.
Infection and Drug Resistance (2023) Vol. Volume 16, pp. 6053-6060
Open Access | Times Cited: 12
Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study
Meiping Chen, Dixuan Jiang, Jiaxi Rang, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Meiping Chen, Dixuan Jiang, Jiaxi Rang, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Azvudine for the Treatment of COVID‐19 in Pre‐Existing Cardiovascular Diseases: A Single‐Center, Real‐World Experience
Wu Liu, Zhong‐Han He, Ling Huang, et al.
Advanced Science (2024) Vol. 11, Iss. 23
Open Access | Times Cited: 4
Wu Liu, Zhong‐Han He, Ling Huang, et al.
Advanced Science (2024) Vol. 11, Iss. 23
Open Access | Times Cited: 4
A Retrospective Analysis of Azvudine in Patients with COVID-19 and Pre-existing Cancer
Fangyu Li, Keao Zheng, Xueyan Qi, et al.
Journal of Cancer (2024) Vol. 15, Iss. 8, pp. 2442-2447
Open Access | Times Cited: 3
Fangyu Li, Keao Zheng, Xueyan Qi, et al.
Journal of Cancer (2024) Vol. 15, Iss. 8, pp. 2442-2447
Open Access | Times Cited: 3
An Update on SARS-CoV-2 Clinical Trial Results—What We Can Learn for the Next Pandemic
Edi Dharmana, Juliane Brun, Michelle L. Hill, et al.
International Journal of Molecular Sciences (2023) Vol. 25, Iss. 1, pp. 354-354
Open Access | Times Cited: 8
Edi Dharmana, Juliane Brun, Michelle L. Hill, et al.
International Journal of Molecular Sciences (2023) Vol. 25, Iss. 1, pp. 354-354
Open Access | Times Cited: 8
Clinical characteristics and risk factors for ZF2001 fully vaccinated inpatients with COVID-19: A retrospective cohort study
Liping Jin, Yating Dian, Yuming Sun, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 2
Liping Jin, Yating Dian, Yuming Sun, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 2
Cost-effectiveness of Azvudine for High-risk Outpatients With Mild-to-moderate Coronavirus Disease 2019 in China
Hui Yang, Zhaojian Wang, C. Wang, et al.
Clinical Therapeutics (2024) Vol. 46, Iss. 9, pp. e1-e5
Closed Access | Times Cited: 2
Hui Yang, Zhaojian Wang, C. Wang, et al.
Clinical Therapeutics (2024) Vol. 46, Iss. 9, pp. e1-e5
Closed Access | Times Cited: 2
Risk factors and prognosis for coronavirus disease 2019 among 131 hemodialysis patients during the Omicron variant epidemic
Wen Wen, Shiming Cai, Yuehong Li, et al.
Renal Failure (2023) Vol. 45, Iss. 1
Open Access | Times Cited: 7
Wen Wen, Shiming Cai, Yuehong Li, et al.
Renal Failure (2023) Vol. 45, Iss. 1
Open Access | Times Cited: 7
Azvudine and nirmatrelvir–ritonavir in hospitalized patients with moderate‐to‐severe COVID‐19: Emulation of a randomized target trial
Yiling Zhou, Yi Liu, Li Jiang, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 12
Open Access | Times Cited: 7
Yiling Zhou, Yi Liu, Li Jiang, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 12
Open Access | Times Cited: 7
Small-molecule anti-COVID-19 drugs and a focus on China’s homegrown mindeudesivir (VV116)
Qiuyu Cao, Yi Ding, Yu Xu, et al.
Frontiers of Medicine (2023) Vol. 17, Iss. 6, pp. 1068-1079
Closed Access | Times Cited: 7
Qiuyu Cao, Yi Ding, Yu Xu, et al.
Frontiers of Medicine (2023) Vol. 17, Iss. 6, pp. 1068-1079
Closed Access | Times Cited: 7
Effectiveness of azvudine against severe outcomes among hospitalized COVID-19 patients in Xinjiang, China: a single-center, retrospective, matched cohort study
Abiden Kapar, Songsong Xie, Zihao Guo, et al.
Expert Review of Anti-infective Therapy (2024) Vol. 22, Iss. 7, pp. 569-577
Closed Access | Times Cited: 1
Abiden Kapar, Songsong Xie, Zihao Guo, et al.
Expert Review of Anti-infective Therapy (2024) Vol. 22, Iss. 7, pp. 569-577
Closed Access | Times Cited: 1
Effectiveness and safety of azvudine in COVID-19: A systematic review and meta-analysis
Bahman Amani, Behnam Amani
PLoS ONE (2024) Vol. 19, Iss. 6, pp. e0298772-e0298772
Open Access | Times Cited: 1
Bahman Amani, Behnam Amani
PLoS ONE (2024) Vol. 19, Iss. 6, pp. e0298772-e0298772
Open Access | Times Cited: 1
Real-world effectiveness and safety of Azvudine in hospitalized patients with SARS-CoV-2 infection: a multicenter, retrospective cohort study
Zhigang Ren, Mengzhao Yang, Guanyue Su, et al.
Journal of Infection (2024) Vol. 89, Iss. 6, pp. 106355-106355
Open Access | Times Cited: 1
Zhigang Ren, Mengzhao Yang, Guanyue Su, et al.
Journal of Infection (2024) Vol. 89, Iss. 6, pp. 106355-106355
Open Access | Times Cited: 1
Effectiveness and Optimal Timing of Azvudine in COVID-19 Patients: A Multi-center Retrospective Study in Beijing, China
Xinjie Han, Han Xiao-bo, Yongqian Wang, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 4
Xinjie Han, Han Xiao-bo, Yongqian Wang, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 4
